RSD-1235. Cardiome.
RSD-1235 is a novel, mixed ion channel antagonist in development by Cardiome Pharma for the potential treatment of heart arrhythmia. By September 2002, phase II trials had been completed and phase III studies were due to commence in 2003.
Department of Physiology and Cell Biology, Ohio State University, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210-1218, USA. billman.1@osu.edu
George E
GE
Billman
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D026902:Potassium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D026941:Sodium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D026902:Potassium Channel Blockers; D026941:Sodium Channel Blockers